Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Peiyuan Mingmu Pills is a Traditional Chinese Medicine (TCM) herbal formulation developed by the Eye Hospital of the China Academy of Chinese Medical Sciences. It is primarily indicated for the treatment of retinitis pigmentosa (RP), a group of rare genetic disorders that involve a breakdown and loss of cells in the retina. In TCM theory, the drug is targeted at patients with the liver–kidney yin deficiency pattern. Clinical evaluation, including a Phase 0 trial in China, has focused on its ability to improve or stabilize the visual field, visual acuity, and electroretinogram (ERG) responses in adult patients. As a complex herbal mixture, its mechanism involves multi-target effects aimed at neuroprotection and improving ocular microcirculation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Peiyuan Mingmu Pills.